SEC Form 4 · accession 0001741850-26-000002
Xeris Biopharma Holdings, Inc. · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nerissa Kreher
Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 6:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001867096
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 1, 2026 | A | 33,582 | $0.00 | A | 33,582 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $8.00 | Jul 1, 2026 | A | 37,910 | A | — | Jul 1, 2036 | Common Stock | 37,910 | 37,910 | D |
Explanation of responses
- F1These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.
- F2These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.
Remarks
Director